Journal article
901PD Association of Progression by Prostate Cancer Working Group (PCWG)-2 Criteria and Survival in Metastatic Castration Resistant Prostate Cancer
Abstract
Background Intermediate endpoints to identify active agents for metastatic castration-resistant prostate cancer (mCRPC) are suboptimal. The Prostate Cancer Working Group (PCWG)-2 guidelines recommend time to clinical or radiographic event endpoints, and discouraged use of endpoints using PSA changes. We investigated the association of progression defined by PCWG-2 guidelines and overall survival (OS). Methods Two trials were analyzed: CS-205, a …
Authors
Sonpavde G; Pond GR; Armstrong AJ; Galsky MD; Wood BA; Wang S; Paolini J; Lechuga M; Smith MR; Michaelson MD
Journal
Annals of Oncology, Vol. 23, , pp. ix297–ix298
Publisher
Elsevier
Publication Date
September 2012
DOI
10.1016/s0923-7534(20)33529-8
ISSN
0923-7534